Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | GABA analogues (anticonvulsants / anti-epileptics). |
| Generic Name : | Vigabatrin |
| Drug description : | Sabril Tablets: white oval scored tablet with tablet name. Sabril Sachet: powder. |
| Presentation : | Sabril Tablets: Vigabatrin 500 mg . Sabril Sachet: Vigabatrin 500 mg . |
| Indications : | Adjunctive treatment of partial Adjunctive treatment of partial seizures with or without secondary generalisation in patients inadequately controlled by, or intolerant to, all other anticonvulsant combinations. Monotherapy for infantile spasms. |
| Adult Dosage : | Initially 1 g daily in single or two divided doses added to existing therapy. Adjust dose in 500 mg weekly increments according to response; maximum 3 g daily. |
| Child Dosage : | Initially 40 mg/kg daily. Maintenance, see data sheet. Infantile spasms, initially 50mg/ kg daily titrated over a one week period if necessary. Doses up to 150 mg/kg daily may be required. |
| Contra Indications : | Pre-existing visual field defect. Lactation. |
| Special Precautions : | History of psychosis or behavioural problems. Elderly, renal impairment. Monitor neurological function. Test visual field before and during therapy; advise patient to report new visual problems - if symptoms develop refer to ophthalmologist and consider discontinuation. Withdraw gradually over 2 - 4 weeks. Pregnancy. |
| Interactions : | Phenytoin. ALT and AST liver tests. |
| Adverse Reactions : | Visual field defects. Agitation, aggression, nervousness, irritability, depression, memory and thought disturbances, paranoid reaction, psychosis, somnolence, fatigue, headache, weight gain, tremor, oedema, dizziness, paraesthesia, sedation, confusion with EEG changes, GI upset, blurred vision, diplopia, nystagmus. Excitation and agitation in children. Increased frequency of seizures in patients with myoclonic seizures. |
| Manufacturer : | Aventis |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org